Rosetta Genomics (ROSG) - microRNA Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rosetta Genomics (ROSG) - microRNA

ROSG 0.430

0.0%

May 21 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (34)	1/18/2009 10:53:53 AM
From: Steve Lokness	Read Replies (1) of 58

The trouble with the test is the data hasn't been very good. Except that it doesn't have to be very good - the existing test are not very good. Someone could have non cancerous or pre cancerous polyps I assume, best removed, but wouldn't show up in a diagnostic. Just thinking out loud. Now that's a valid point. At what point are the markers identifiable? Perhaps if rosetta wants an exit they can make noise about mirna's for fetal dx. "Wants out"? Not sure what you are saying here. Why would Rosetta want an exit? Assuming they think their test is valid. steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next